E. Campigna

发表

In vivo Therapeutic Synergism of Anti–Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas

B. Robert, I. Navarro-Teulon, F. Bibeau, 2007, Clinical Cancer Research.

Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional protein.

B. Robert, I. Navarro-Teulon, A. Pèlegrin, 2008, Protein engineering, design & selection : PEDS.

Biodistribution of a Bispecific Single-chain Diabody and Its Half-life Extended Derivatives*

R. Kontermann, B. Robert, R. Stork, 2009, The Journal of Biological Chemistry.

In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.

C. Bascoul-Mollevi, B. Robert, A. Pèlegrin, 2012, Neoplasia.